Latash Investments LLC bought a new stake in Aquestive Therapeutics, Inc. (NASDAQ:AQST – Free Report) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 243,134 shares of the company’s stock, valued at approximately $1,011,000. Aquestive Therapeutics comprises 0.7% of Latash Investments LLC’s investment portfolio, making the stock its 7th largest position.
A number of other hedge funds and other institutional investors have also bought and sold shares of AQST. Wasatch Advisors LP increased its position in Aquestive Therapeutics by 57.8% during the second quarter. Wasatch Advisors LP now owns 1,385,843 shares of the company’s stock worth $5,765,000 after buying an additional 507,527 shares during the last quarter. Walleye Capital LLC acquired a new stake in shares of Aquestive Therapeutics in the second quarter valued at approximately $1,175,000. Simplify Asset Management Inc. acquired a new stake in shares of Aquestive Therapeutics in the first quarter valued at approximately $972,000. Bleakley Financial Group LLC bought a new position in shares of Aquestive Therapeutics during the 1st quarter worth approximately $563,000. Finally, Everstar Asset Management LLC boosted its stake in shares of Aquestive Therapeutics by 60.4% during the 1st quarter. Everstar Asset Management LLC now owns 553,181 shares of the company’s stock worth $2,296,000 after acquiring an additional 208,381 shares during the period. Institutional investors own 32.45% of the company’s stock.
Aquestive Therapeutics Stock Performance
AQST opened at $4.59 on Thursday. Aquestive Therapeutics, Inc. has a fifty-two week low of $2.93 and a fifty-two week high of $7.55. The company has a market capitalization of $576.09 million, a P/E ratio of -7.06 and a beta of 1.49. The stock has a fifty day moving average of $4.16 and a 200-day moving average of $4.11.
Insider Transactions at Aquestive Therapeutics
In other Aquestive Therapeutics news, Director Julie Krop sold 25,000 shares of the stock in a transaction that occurred on Tuesday, June 23rd. The shares were sold at an average price of $5.02, for a total transaction of $125,500.00. Following the transaction, the director owned 25,000 shares in the company, valued at $125,500. This represents a 50.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.81% of the stock is owned by corporate insiders.
Wall Street Analysts Forecast Growth
A number of research firms recently weighed in on AQST. Weiss Ratings reissued a “sell (d-)” rating on shares of Aquestive Therapeutics in a report on Friday, July 17th. Wall Street Zen downgraded Aquestive Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Finally, Oppenheimer started coverage on shares of Aquestive Therapeutics in a research report on Friday, April 24th. They set an “outperform” rating and a $8.00 price objective for the company. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $8.50.
View Our Latest Research Report on AQST
Aquestive Therapeutics Profile
Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.
The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.
Read More
- Five stocks we like better than Aquestive Therapeutics
- Bloom Energy’s AI Surge Meets a Valuation Reality Check
- Target Is Winning Shoppers Back—Can the Rally Reach $180?
- IonQ’s Space Contract Points to a New Frontier for Quantum Investors
- Is Apple’s AI Strategy Smarter Than Skeptics Think?
Want to see what other hedge funds are holding AQST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aquestive Therapeutics, Inc. (NASDAQ:AQST – Free Report).
Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
